Nimish P. Shah - 03 Sep 2026 Form 4 Insider Report for Apogee Therapeutics, Inc. (APGE)

Reporting relationship: Director
Issuer ticker: APGE
Reported as of: 03 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Sep 2026, 16:39:06 UTC
Prior SEC filing: 11 Jun 2026
Next SEC filing: 10 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ Matthew Batters, as attorney-in-fact for Nimish Shah

Key filing fact

Nimish P. Shah filed Form 4 for Apogee Therapeutics, Inc. (APGE) on 03 Sep 2026.

Key facts

This page summarizes Nimish P. Shah's Form 4 filing for Apogee Therapeutics, Inc. (APGE).
7 reported transactions and 6 derivative rows are listed below.
Accepted by SEC: 03 Sep 2026, 16:39.

Change

Previous filing in this sequence was filed on 11 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001698082 Primary reporting owner

Shah Nimish P

Relationship: Director
Address: C/O APOGEE THERAPEUTICS, INC., 1 LETTERMAN DRIVE, BUILDING B, SAN FRANCISCO
Signature: /s/ Matthew Batters, as attorney-in-fact for Nimish Shah
Signature date: 03 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

APGE transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -1,750,000
Change %: -100%
Price: $135.11^*
Shares after: 0
Date: 03 Sep 2026
Ownership: See footnote
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

APGE transaction Derivative

Non-Voting Common Stock

Disposed to Issuer

Transaction value
Shares: -6,743,321
Change %: -100%
Price: $135.11^*
Shares after: 0
Date: 03 Sep 2026
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 6,743,321
Exercise price: $0.000000
Footnotes: F2, F3, F4

APGE transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -47,758
Change %: -100%
Price
Shares after: 0
Date: 03 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 47,758
Exercise price: $17.00
Footnotes: F5, F6, F7

APGE transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -10,370
Change %: -100%
Price
Shares after: 0
Date: 03 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,370
Exercise price: $43.85
Footnotes: F5, F6, F7

APGE transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -14,461
Change %: -100%
Price
Shares after: 0
Date: 03 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 14,461
Exercise price: $41.66
Footnotes: F5, F6, F7

APGE transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -7,657
Change %: -100%
Price
Shares after: 0
Date: 03 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,657
Exercise price: $85.00
Footnotes: F5, F6, F7

APGE transaction Derivative

Pre-Funded Warrants (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -365,853
Change %: -100%
Price
Shares after: 0
Date: 03 Sep 2026
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 365,853
Exercise price
Footnotes: F6, F8, F9, F10

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Nimish P. Shah is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 10 footnotes

Footnote F1

The reported securities, which were disposed of in connection with the acquisition of the Issuer by AbbVie Inc. (the "Merger"), represent (i) 460,075 shares of the Issuer's common stock ("Common Stock") held by Venrock Healthcare Capital Partners III, L.P. ("VHCP III"), (ii) 46,025 shares held by VHCP Co-Investment Holdings III, LLC ("VHCP Co-III") and (iii) 1,243,900 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG").

Footnote F2

VHCP Management III, LLC ("VHCPM III") is the sole general partner of VHCP III and the sole manager of VHCP Co-III. VHCP Management EG, LLC ("VHCPM EG") is the sole general partner of VHCP EG. Dr. Bong Koh and Nimish Shah are the voting members of VHCPM III and VHCPM EG. Dr. Koh, Mr. Shah, VHCPM III and VHCPM EG disclaim beneficial ownership over all shares held by VHCP III, VHCP Co-III, and VHCP EG, except to the extent of their respective indirect pecuniary interests therein.

Footnote F3

The Non-Voting Common Stock was convertible at any time and had no expiration date.

Footnote F4

The reported securities, which were disposed of in connection with the Merger, represent (i) 2,495,319 shares of Non-Voting Common Stock held directly by VHCP III, (ii) 249,522 shares of Non-Voting Common Stock held directly by VHCP Co-III and (iii) 3,998,480 shares of Non-Voting Common Stock held directly by VHCP EG.

Footnote F5

The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.

Footnote F6

Each reported option and warrant was disposed of in connection with the Merger in exchange for a cash payment equal to the excess of $135.11 (the per share merger consideration) over the exercise price of such option or warrant.

Footnote F7

Under an agreement between the Reporting Person and Venrock Management, LLC (the "Management Company"), the Reporting Person is deemed to hold the reported option and the shares underlying the option for the sole benefit of the Management Company. The Reporting Person disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein.

Footnote F8

The exercise price of each reported warrant is $0.00001 per share.

Footnote F9

The reported warrants had no expiration date and were exercisable immediately upon grant.

Footnote F10

The reported warrants are held directly by Venrock Opportunities Fund, L.P. ("VOF"). Venrock Opportunities Management, LLC ("VO Management") is the general partner of VOF. The Reporting Person is a voting member of VO Management and expressly disclaims beneficial ownership over all shares held by VOF except to the extent of his indirect pecuniary interests therein.